Last reviewed · How we verify

NCT06974162

Metagenomics for Ocular Inflammation

Recruiting now Last updated 20 November 2025
What this trial tests

trial testing Metagenomic sequencing of aqueous humor in Uveitis in 36 participants. Currently enrolling.

Timeline
12 June 2025
Primary endpoint
12 June 2026
12 July 2026

Quick facts

Lead sponsorMoorfields Eye Hospital NHS Foundation Trust
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment36
Start date12 June 2025
Primary completion12 June 2026
Estimated completion12 July 2026
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Moorfields Eye Hospital NHS Foundation Trust

Who can join

Eligibility, any sex, with Uveitis or Aqueous Humor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to apply a diagnostic test called 'metagenomic sequencing' to identify the involvement of potential infections in patients with ocular inflammation, where this hasn't been detected by currently available standard testing. For many people with ocular inflammation, no cause is ever found for their disease. In some cases, an infection or infectious trigger is suspected, but currently available tests are inadequate. Metagenomic sequencing can identify almost every globally known infection (bacteria, virus, fungi, parasites) in a sample. Therefore, it has the potential to identify an infection that has caused or triggered ocular inflammation, and as a consequence may help to identify specific treatments. It has the potential to improve our understanding of how to diagnose and treat people with this problem. This study will allow us to test the technique that has been previously optimised for brain infections, on ocular fluids. Participants will be 18 years of age or over and have active ocular inflammation which is suspected to be due to an infection, or an autoimmune process which has been triggered by an infection, but identification of this infection has not been possible using the investigations available as part of standard NHS care. Participants will be identified by the treating clinical team as requiring a sample of fluid from inside of the eye, and some of this fluid will be sent for metagenomic sequencing alongside standard testing. This study will be conducted at Moorfields Eye Hospital, London and will last for approximately a year. Participants will undergo additional non-invasive ocular imaging on the day of their clinic visit, but will not have to attend any additional research visits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Uveitis

Currently open trials in the same condition.

Other Moorfields Eye Hospital NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06974162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing